{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:07:18Z","timestamp":1772712438556,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.suronc.2018.05.004","type":"journal-article","created":{"date-parts":[[2018,5,6]],"date-time":"2018-05-06T09:48:31Z","timestamp":1525600111000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rationale for the administration of systemic 5-FU in combination with heated intraperitonal oxaliplatin"],"prefix":"10.1016","volume":"27","author":[{"given":"D.","family":"Badrudin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-8002","authenticated-orcid":false,"given":"F.A.","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pichette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.suronc.2018.05.004_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2018.05.004_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis","volume":"254","author":"Quenet","year":"2011","journal-title":"Ann. Surg."},{"issue":"7","key":"10.1016\/j.suronc.2018.05.004_bib3","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1245\/s10434-012-2264-z","article-title":"The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study","volume":"19","author":"Hompes","year":"2012","journal-title":"Ann. Surg Oncol."},{"issue":"7","key":"10.1016\/j.suronc.2018.05.004_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jso.23431","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer","volume":"108","author":"Gervais","year":"2013","journal-title":"J.\u00a0Surg. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2018.05.004_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2018.05.004_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"22","key":"10.1016\/j.suronc.2018.05.004_bib7","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2006.06.1440","volume":"24","author":"Giacchetti","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2018.05.004_bib8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2018.05.004_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01212608","article-title":"Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells","volume":"123","author":"Rietbroek","year":"1997","journal-title":"J.\u00a0Canc. Res. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.suronc.2018.05.004_bib10","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","article-title":"A\u00a0systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin","volume":"16","author":"Cao","year":"2009","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2018.05.004_bib11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/SLA.0b013e3182193143","article-title":"Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model","volume":"254","author":"Piche","year":"2011","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.suronc.2018.05.004_bib12","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.5414\/CP202120","article-title":"Development of a HPLC method to determine 5-fluorouracil in plasma: application in pharmacokinetics and steady-state concentration monitoring","volume":"52","author":"Pi","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Therapeut."},{"issue":"2 Suppl 5","key":"10.1016\/j.suronc.2018.05.004_bib13","first-page":"32","article-title":"Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer","volume":"25","author":"Bleiberg","year":"1998","journal-title":"Semin. Oncol."},{"issue":"13","key":"10.1016\/j.suronc.2018.05.004_bib14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S1470-2045(14)70486-3","volume":"15","author":"Schmoll","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2018.05.004_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00280-011-1700-2","article-title":"Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin","volume":"69","author":"Afzal","year":"2012","journal-title":"Canc. Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.suronc.2018.05.004_bib16","first-page":"575","article-title":"Evaluation of in\u00a0vitro cytotoxicity of oxaliplatin and 5-fluorouracil in human colon cancer cell lines: combination versus sequential exposure","volume":"25","author":"Failli","year":"2011","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"issue":"1","key":"10.1016\/j.suronc.2018.05.004_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clpt.2004.03.008","article-title":"Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin","volume":"76","author":"Joel","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.suronc.2018.05.004_bib18","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1158\/1535-7163.MCT-14-0748","article-title":"The 1,2-Diaminocyclohexane Carrier ligand in oxaliplatin induces p53-Dependent transcriptional repression of factors involved in thymidylate biosynthesis","volume":"14","author":"Kiyonari","year":"2015","journal-title":"Mol. Canc. Therapeut."},{"issue":"13","key":"10.1016\/j.suronc.2018.05.004_bib19","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.suronc.2018.05.004_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A\u00a0systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol."},{"issue":"5","key":"10.1016\/j.suronc.2018.05.004_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-fluorouracil induced cardiotoxicity: review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol. J."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740417303493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740417303493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:17:42Z","timestamp":1760757462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740417303493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0960740417303493"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2018.05.004","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for the administration of systemic 5-FU in combination with heated intraperitonal oxaliplatin","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2018.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}